Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 6/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | CPS1 | P31327 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10156660 | 0.98 | HPGD (0.67) | MEN1KMT2AHPGDLMNATSHR | |
| SCHEMBL21650784 | 0.88 | ALDH1A1 (0.61) | MEN1KMT2AHPGDLMNATSHR | |
| SCHEMBL7503096 | 0.88 | ALDH1A1 (0.56) | MEN1KMT2AHPGDLMNATSHR | |
| SCHEMBL18754001 | 0.87 | ALDH1A1 (0.55) | MEN1KMT2AHPGDLMNATSHR | |
| SCHEMBL15651032 | 0.87 | ALDH1A1 (0.60) | MEN1KMT2AHPGDLMNATSHR | |
| SCHEMBL18753369 | 0.85 | ALDH1A1 (0.52) | MEN1KMT2AHPGDLMNATSHR | |
| SCHEMBL22172135 | 0.85 | ALDH1A1 (0.52) | MEN1KMT2AHPGDLMNATSHR | |
| SCHEMBL3925726 | 0.84 | HTT (0.55) | MEN1KMT2AHPGDLMNATSHR | |
| SCHEMBL10293595 | 0.83 | MEN1 (0.67) | MEN1KMT2AHPGDLMNATSHR | |
| SCHEMBL17502660 | 0.82 | KMT2A (0.65) | MEN1KMT2AHPGDLMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020131627-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | ARRAY BIOPHARMA INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| EP-1360170-A1 | CARBOXYLIC AMIDES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-11-12 | — | — | EP | disclosed |
| US-20020151595-A1 | Carboxylic acid amides having antithrombotic activity | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-10-17 | — | — | US | disclosed |
| WO-2002062748-A1 | CARBOXYLIC AMIDES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151595-A1 | Carboxylic acid amides having antithrombotic activity | SERPINC1, TFPI, F2 | MEN1 2915/4885KMT2A 545/4885HPGD 1175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.